As a first step in this direction, this study used a MiniPDX model to confirm the effect of a PKM2 agonist on the proliferation of HLA-F–knockdown trophoblastic cells, and the results suggest that a PKM2 agonist may represent an avenue to explore the treatment of preeclampsia. Here, HLA-F is linked to preeclampsia.